ERBB2 and breast carcinoma: Trastuzumab emtansine (T-DM1) was the first antibody-drug conjugate (ADC) approved in second line for treatment of metastatic HER2+ breast cancer after progression on trastuzumab and pertuzumab, based on the EMILIA trial [30].